You seem to be a tad confused by the whole WMT vs DMT situation.
Let me clarify: The cash costs that PLS reports are in terms of DMT not WMT.
Furthermore when they make reference to sales pricing it is in terms of DMT CIF China, just like their cost reporting. Both costs and pricing when mentioned in quarterlies is stated in USD.
Now let me be clear this is not an AISC figure, but is more comprehensive than some peers IMO.
My personal opinion is that while PLS did make a considerable operating loss in FY20 and has the potential to do so again for FY 21, it is NOT currently operating at a "severe" loss and has a healthy balance sheet with a comfortable level of funds to meet commitments.
Given the current trajectory of pricing for SC6, IMO PLS is either at the point of or will soon be achieving operating profits.
Ann: December 2020 Quarterly Activities Report, page-102
Add PLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.98 |
Change
-0.020(0.67%) |
Mkt cap ! $8.972B | |||
| Open | High | Low | Value | Volume |
| $2.92 | $2.98 | $2.90 | $38.78M | 13.16M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15056 | $2.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.98 | 89928 | 9 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PLS (ASX) Chart |